Appendix 4E & Preliminary Final Report
Filed with ASX · · 11 pages · English
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- June 2026 Quarterly Activity Report & Appendix 4C
- Board, Management Changes, Expenditure Reductions, RDTI Loan
- Reinstatement to Official Quotation
- CYP-001 GvHD Trial Primary Evaluation Results
- Suspension from Quotation
Later from Cynata Therapeutics
- Notification under Listing Rule 4.3D
- R&D Tax Incentive Loan Facility Extension
- Cynata Receives R&D TI Refund & Repays R&D TI Loan
- Termination of At-the-Market Subscription Deed
- Entitlement Offer & Unmarketable Parcel Sale Facility
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics